Hold. CDNA scores well on growth (72/100) with consistent revenue expansion, but trades at 39× forward earnings with maximal vulnerability exposure—reliant on R&D intensity and execution timing with minimal financial cushion. Leadership alignment (62/100) lacks founder-CEO concentration or visible long-term optionality signals. Suitable for growth portfolios, but limited margin of safety at current valuation.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CDNA:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 68/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates CDNA (CDNA) at 68/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. CDNA scores well on growth (72/100) with consistent revenue expansion, but trades at 39× forward earnings with maximal vulnerability exposure—reliant on R&D intensity and execution timing with minimal financial cushion. Leadership
CDNA's current Stocky Verdict is 68/100, placing it in the "Hold" band. This composite combines a 72/100 Compounder score, 62/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for CDNA yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
CDNA scores 62/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
CDNA's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to CDNA.
Sign up free and unlock the full analysis on CDNA — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for CDNA in the app.
